Recent Updates
Recently added Catalysts

IW-1973

Phase 2

Type 2 Diabetes Mellitus With Diabetic Nephropathy | Small molecule | Metabolic |Akebia Therapeutics, Inc.|Last Updated: Sep 15, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment156
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03217591A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by AlbuminuriaPHASE2 COMPLETED 156Aug 1, 2017Aug 20, 2019Sep 15, 202254 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Study Drug-Related TEAEs
Day 1 up to Day 115

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as those AEs that started or worsened in severity after the initiation of study drug administration. Causality relationship to study drug was per Investigator assessment.

Percent Change From Baseline in Urine Albumin Creatinine Ratio (UACR) Over Weeks 8 and 12
Baseline; Week 8 to Week 12

Urine samples were collected for the analysis of UACR. UACR (milligrams per gram \[mg/g\]) was calculated as urine albumin (mg per deciliter \[mg/dL\]) / urine creatinine (g/dL). Change from Baseline was calculated as the average of the UCAR values at Weeks 8 and 12 minus the Baseline value. Data were analyzed using a mixed-effects model repeated measures (MMRM) analysis with change from Baseline in log-transformed UACR as the response variable, treatment, visit, treatment-by visit interaction, and Baseline estimated glomerular filtration rate stratum as fixed effects, Baseline log-transformed UACR and Baseline mean arterial pressure as covariates, and unstructured as the variance-covariance structure.

Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
IW-1973 Low DoseEXPERIMENTALAdministered daily for 12 weeks
IW-1973 High DoseEXPERIMENTALAdministered daily for 12 weeks
PlaceboPLACEBO_COMPARATORPlacebo to match experimental drug administered daily for 12 weeks
Interventions
NameTypeDescription
IW-1973DRUGOral Tablet
PlaceboDRUGOral Tablet
Unlock Study Design Details
Eligibility Criteria
Age Range25 Years — 75 Years
SexALL
Healthy VolunteersNo
Study Sites54

Key Inclusion Criteria: * Patient is an ambulatory male or female from 25 to 75 years old at the Screening Visit. * Patient has type 2 diabetes diagnosed by a physician or nurse practitioner ≥6 months before the Screening Visit, has been on ≥1 antihyperglycemic medication for ≥12 weeks preceding th...

Countries:United States
Unlock Eligibility Criteria